Scientists Isolate Antibody that Neutralizes Hepatitis C

Scientists Isolate Antibody that Neutralizes Hepatitis C
May 11, 2009
Printer-friendly version

Although not yet tested in humans, Massachusetts researchers have found an antibody to the Hepatitis C virus that can prevent and help clear Hepatitis C infection.

New Antibody Prevents Infection By Hepatitis C Virus

Wednesday, May 06, 2009

Taking aim at a leading cause of liver failure in the United States, a team of scientists at the Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) has developed a human monoclonal antibody that neutralizes the Hepatitis C virus (HCV). The new antibody effectively neutralized the virus in culture, and then prevented infection by the virus in a pre-clinical animal model of the disease.

Details of the research were presented April 23 in Copenhagen, Denmark at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL). "We are pleased with the progress of this program," said Donna Ambrosino, MD, executive director of the MBL and a professor of pediatrics at the Medical School. "This antibody shows significant efficacy against the virus."

In the current study, MBL scientists injected transgenic mice (HuMAb Mouse® technology, Medarex, Inc.) with elements of HCV and then painstakingly searched for individual human antibodies produced in the mice that would recognize and bind to the HCV's outer coat, known as the glycoprotein. Once they found human antibodies that looked promising, they evaluated in vitro the ability of those antibodies to neutralize the virus and selected a lead candidate antibody for further characterization. Collaborative work with clinical researchers from the Department of Medicine at the Medical School's Worcester campus demonstrated that this antibody, now known as MBL-HCV1, was able to bind tightly with all genotypes of HCV tested from infected patient samples.

MBL-HCV1 was then tested off-site on three non-human primates. In that study, one animal received no antibody, one a low dose of the new antibody, and one a higher dose. Then all three animals were exposed to HCV. The animals with low or no antibody dosages developed HCV infections, but the animal with the higher dose was protected. Subsequently, researchers gave the high-dose of the antibody to the animal that originally received no antibody, and in that case the HCV was cleared from that animal's system. "These results are encouraging as a possible treatment for HCV infected patients, but more work needs to be done before we know how effective it will be in people," Dr. Ambrosino noted.

HCV attacks the liver and can eventually lead to liver failure. According to the U.S. Centers for Disease Control and Prevention, 3.2 million Americans are chronically infected with HCV and some 10,000 die annually of the disease. Globally, as many as 170 million people are estimated to suffer from HCV infection. For the most serious cases of HCV that do not respond to antiviral drugs, liver transplantation is the only option.

Typically 2,000 to 4,000 liver transplants are done each year in the United States (far less than the number of people on the waiting list for available organs). Transplantation can be a life saving treatment; however, in nearly all cases the patient's new liver is eventually infected by HCV because the virus remains in the patient's bloodstream during surgery. The powerful antiviral drugs now used to attack HCV prior to end-stage liver failure are not routinely used during surgery due to the patients' weakened condition and because of the strong medication used to avoid rejection of the new liver. After re-infection with HCV, nearly 40 percent of patients suffer rapid liver failure.

To close that clinical gap, the new antibody developed at MBL is designed to be a therapy shortly before and after transplant surgery. By giving a patient the new antibody before and during the time when the donor liver is implanted, researchers hope the HCV virus left in the bloodstream will be neutralized and rendered unable to infect the new liver. Then, because monoclonal antibodies are highly specific and typically have little or no side-effects, additional dosages of the new antibody could, theoretically, be given immediately after transplant surgery to continue neutralizing any remaining virus.

It is also possible, researchers theorize, that the antibody could be used in combination with new antiviral drugs for treatment in patients with newly diagnosed HCV infection. Use of the new antibody for both liver transplant patients and in newly diagnosed HCV patients will now be further evaluated. A Phase 1 human clinical trial of MBL-HCV1 in healthy subjects is expected to begin later this year.

Source-Eurekalert
SRM

URL for Article Source:
http://www.medindia.net/news/New-Antibody-Prevents-Infection-By-Hepatitis-C-Virus-50949-2.htm

Posted by Editors at May 11, 2009 10:11 AM
Video ClipsPodcastsSite Topics
HCV SymptomsYou'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.

Lab TestsWhat they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.

Hepatitis C GenotypesLearn about Hepatitis C Genotypes and their variants.

Viral LoadIncludes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.

HCV Medicines Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.

Hepatitis C Doctors A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.

Biopsy InfoA comprehensive resource of information relating to the liver biopsy.

CirrhosisMany discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.

Liver CancerLiver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.

Liver Disease MedicinesAn exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.

Hep-Central Email ListSign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.

HCV LinksConvenient links to other sites external to Hepatitis-Central.

Mother/Child TransmissionDiscussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.

HCV Natural RemediesA number of herbal products useful in the management of liver disease.

HCV BooksRecommended reading for those interested in hepatitis information.

Hepatitis C Forum A Bulletin Board for discussions on hepatitis, treatments, etc.

Hepatitis C ActivismAn easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.
Search R&T News
Go! Questions? Comments?
Questions or Comments about any articles?
Contact Us.

Author Biographies Copyright ©1994-2009 Hepatitis Central. Information at this website is for educational purposes